Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Boston, Massachusetts
- Most recent report
- 10-Q, filed Nov 3, 2026
- Incorporated
- Delaware
- Filings on record
- 870 filings
- On EDGAR
- CIK 1434647
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer, Smaller reporting company
Financials 8 of 48
News 8 of 209
Prospectuses and Registrations 8 of 82
- S-8 Registration statement for an employee plan Mar 9, 2026
- S-8 Registration statement for an employee plan Mar 13, 2025
- 424B5 Prospectus supplement for an offering Aug 9, 2024
- 424B5 Prospectus supplement for an offering Aug 8, 2024
- 424B2 Prospectus supplement for an offering Jul 12, 2024
- S-3 Shelf registration statement Jun 4, 2024
- 424B3 Prospectus supplement for an offering Apr 10, 2024
- S-3/A Shelf registration statement, amended Apr 8, 2024
Proxies 8 of 46
- DEF 14A Proxy statement for a shareholder vote Apr 20, 2026
- PRE 14A Preliminary proxy statement Apr 6, 2026
- DEFA14A Extra proxy material May 21, 2025
- DEFA14A Extra proxy material May 8, 2025
- DEFA14A Extra proxy material Apr 21, 2025
- DEFA14A Extra proxy material Apr 21, 2025
- DEFA14A Extra proxy material Apr 7, 2025
- DEFA14A Extra proxy material Mar 31, 2025
Ownership 8 of 387
- SCHEDULE 13G/A Large holder reported a passive stake, amended Nov 5, 2026
- 4 Insider reported a trade Oct 13, 2026
- 144 Notice of a proposed sale of restricted stock Oct 13, 2026
- 4 Insider reported a trade Aug 17, 2026
- 144 Notice of a proposed sale of restricted stock Aug 14, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- 4 Insider reported a trade Aug 12, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 6, 2026
Other 8 of 98
Everything here comes from Zevra Therapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.